Castration-resistant prostate cancer: why should urologists care? Report as inadecuate




Castration-resistant prostate cancer: why should urologists care? - Download this document for free, or read online. Document in PDF available to download.

Revista Urología Colombiana 2016, XXV 3

Author: Judd W. Moul

Source: http://www.redalyc.org/


Teaser



Revista Urología Colombiana ISSN: 0120-789X revistaurologiacolombiana@scu.org.co Sociedad Colombiana de Urología Colombia Moul, Judd W. Castration-resistant prostate cancer: Why should urologists care? Revista Urología Colombiana, vol.
XXV, núm.
3, septiembre-diciembre, 2016, pp.
198-200 Sociedad Colombiana de Urología Available in: http:--www.redalyc.org-articulo.oa?id=149148397002 How to cite Complete issue More information about this article Journals homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative Documento descargado de http:--www.elsevier.es el 23-11-2016.
Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato. Urol Colomb.
2016;25(3):198---200 www.elsevier.es-uroco EDITORIAL Castration-resistant prostate cancer: Why should urologists care? Cáncer de próstata resistente a la castración: ¿por qué les debe importar a los urólogos? Judd W.
Moul Division of Urology, Duke Cancer Institute, Duke University, Durham, North Carolina, United States It seems like yesterday when I was sitting at the American Society of Clinical Oncology (ASCO) Program Committee section for Genitourinary oncology as part of a multi-disciplinary team of medical oncologists, urologists and radiation oncologists deciding what prostate cancer abstracts to consider for the annual meeting a few months later.
At that time, we were so excited that finally two GU abstracts were making the ‘‘big time’’ as key showcased DOI of original article: http:--dx.doi.org-10.1016-j.uroco.2016.07.001 E-mail address: judd.moul@duke.edu http:--dx.doi.org-10.1016-j.uroco.2016.07.002 0120-789X- papers.
I am referring to the seminal work of Eisenberger et al.
and Petrylak and colleagues who were presenting overall survival benefit of Docetaxel in CRPC, which at that time was stil...





Related documents